Search research articles
Contact Us
Filters
Showing results (121-130 of 138) with videos related to
Page
of 14
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
October 5, 2020
Role of oxidative stress in clofazimine-induced cardiac dysfunction in a zebrafish model
Phoebe C I Ng, Judy Y W Chan, Ross K K Leung, et al.
Oncogene
|
October 13, 2015
JRK is a positive regulator of β-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer
L Pangon, I Ng, M Giry-Laterriere, et al.
Cell Reports
|
March 2, 2022
dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region
Shiri Levy, Logeshwaran Somasundaram, Infencia Xavier Raj, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 16, 2007
Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives
A Chris Krueger, Darold L Madigan, Brian E Green, et al.
Hepatology (Baltimore, Md.)
|
June 30, 2019
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study
Maureen M Jonas, Robert H Squires, Susan M Rhee, et al.
Antimicrobial Agents and Chemotherapy
|
November 1, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
Teresa I Ng, Rakesh Tripathi, Thomas Reisch, et al.
Hepatology (Baltimore, Md.)
|
November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
Fred Poordad, Stanislas Pol, Armen Asatryan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
Jürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 17, 2009
Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket
Kent D Stewart, Jeffrey R Huth, Teresa I Ng, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 138) with videos related to
Sort By:
Page
of 14
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
October 5, 2020
Role of oxidative stress in clofazimine-induced cardiac dysfunction in a zebrafish model
Phoebe C I Ng, Judy Y W Chan, Ross K K Leung, et al.
Oncogene
|
October 13, 2015
JRK is a positive regulator of β-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer
L Pangon, I Ng, M Giry-Laterriere, et al.
Cell Reports
|
March 2, 2022
dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region
Shiri Levy, Logeshwaran Somasundaram, Infencia Xavier Raj, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 16, 2007
Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives
A Chris Krueger, Darold L Madigan, Brian E Green, et al.
Hepatology (Baltimore, Md.)
|
June 30, 2019
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study
Maureen M Jonas, Robert H Squires, Susan M Rhee, et al.
Antimicrobial Agents and Chemotherapy
|
November 1, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
Teresa I Ng, Rakesh Tripathi, Thomas Reisch, et al.
Hepatology (Baltimore, Md.)
|
November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
Fred Poordad, Stanislas Pol, Armen Asatryan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
Jürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 17, 2009
Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket
Kent D Stewart, Jeffrey R Huth, Teresa I Ng, et al.
Page
of 14